A surreal family tree of blood cells, highlighting DNA mutations.

Decoding the Blueprint of Blood: How Mutations Reveal Secrets of Lifelong Health

Reese Marlowe monogram
Reese Marlowe in Health & Wellness October 2026 • 4 min read.

"New research uncovers how somatic mutations in blood cells chart lineage, age-related changes, and potential risks for diseases like leukemia."


Imagine our blood as a vast, ever-changing city. Within this city, cells are constantly dividing, growing, and aging. As they do, they accumulate tiny changes, or mutations, in their DNA. These mutations, once seen as simply errors, are now recognized as potential maps, guiding us to understand the history and future of our blood.

A groundbreaking study published in Cell Reports sheds light on how these mutations, specifically somatic mutations (those acquired after conception), can reveal the lineage relationships between different blood cells, the rate at which they accumulate over a lifetime, and even the factors that contribute to diseases like leukemia. This research opens new doors to understanding the complex dynamics of our blood system and how it impacts our overall health.

Think of it like tracing a family tree. By analyzing the genetic mutations in our blood cells, scientists are beginning to piece together a detailed picture of where these cells came from, how they've evolved, and what risks they might face along the way. This knowledge could lead to innovative strategies for preventing and treating blood-related disorders.

AI Search Multiple angles on this topic

Defining CHIP and CCUS

Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS) are defined by somatic mutations in genes associated with myeloid neoplasms. Both conditions use a variant allele fraction of 0.02 or greater as a threshold. CHIP is identified without cytopenia, whereas CCUS is identified when cytopenia is present.

Mutation-Based Lineage Tracing

Somatic mutations in nuclear or mitochondrial DNA can serve as natural lineage markers for tracing human blood-cell development. Researchers have used these mutations to construct developmental lineage trees and examine multipotent developmental clones. However, research on somatic mosaicism and clonal hematopoiesis has been based predominantly on individuals of European ancestry, limiting how broadly existing findings may apply.

Mutations as Natural Barcodes

Naturally occurring somatic mutations in blood cells can retrospectively trace fetal or adult hematopoiesis. Mutations in mitochondrial and nuclear genomes can function as natural “barcodes,” allowing researchers to generate phylogenetic relationships between cells. This approach helped produce developmental lineage trees showing a polyclonal architecture and evidence that developmental clones can be multipotent.

The Mutation Story: Reading the Code of Our Blood Cells

A surreal family tree of blood cells, highlighting DNA mutations.

The core of this research lies in cataloging mutations. Scientists meticulously analyzed the genomes of hematopoietic stem and progenitor cells (HSPCs). These are the seed cells of our blood system, responsible for creating all the different types of blood cells we need to stay alive. By comparing the genetic makeup of these HSPCs from individuals of different ages (including cord blood samples to represent mutations present at birth), researchers were able to draw fascinating conclusions.

The study revealed that mutations accumulate gradually throughout life, at a rate of approximately 14 base substitutions per year. The majority of these mutations are acquired after birth, suggesting they are driven by ongoing processes within the body rather than inherited factors. This discovery is crucial because it highlights the potential for interventions to mitigate these mutagenic processes and potentially reduce the risk of disease.

Here's what they discovered about mutations:
  • Steady Accumulation: Mutations build up at a consistent rate from birth.
  • Endogenous Culprits: Most mutations come from natural, internal processes.
  • Leukemia Link: The mutational patterns in normal blood cells are similar to those found in acute myeloid leukemia (AML), implying that the disease arises from these same underlying processes combined with specific driver mutations.
AI Search Multiple angles on this topic

Expanding Views of Clonal Hematopoiesis

A Nature Genetics analysis examined whole-blood exome sequencing from 200,618 UK Biobank individuals aged 40–70 years to identify somatic mutations in blood. Recent reviews examine CHIP in relation to somatic mutations in blood and cardiovascular tissues, with particular attention to systemic inflammation. Another 2025 review describes CHIP as a risk factor not only for hematologic malignancies but also for chronic inflammation and diverse non-hematologic diseases.

Limits of Causal Interpretation

The association between somatic mutation-driven clonal hematopoiesis and atherosclerotic cardiovascular disease may reflect shared consequences of aging or other confounding factors. Evidence also indicates that most clones began expanding before the subject reached 40 years of age. Yet only 22% of those clones had known driver mutations, underscoring limits in explaining clonal expansion from currently recognized drivers alone.

Newly Recognized Drivers

An analysis of somatic mutations in blood exomes from 200,618 individuals identified previously unrecognized genes driving age-related clonal hematopoiesis. The findings broaden the set of genetic changes that may contribute to clonal expansion. They also provide a larger basis for comparing recognized and newly identified drivers in blood.

One of the most intriguing findings was the similarity in mutation patterns between normal HSPCs and those found in acute myeloid leukemia (AML). This suggests that the development of leukemia isn't necessarily due to dramatically increased mutagenesis, but rather the selection and expansion of cells that have acquired specific mutations that give them a growth advantage. This subtle but critical difference in understanding could revolutionize how we approach leukemia prevention and treatment.

A New Chapter in Blood Research

This study offers a powerful framework for understanding the intricate world of our blood cells. By deciphering the mutational history of these cells, scientists are gaining unprecedented insights into lineage relationships, age-related changes, and the origins of blood disorders. This knowledge paves the way for future research focused on developing targeted interventions to promote lifelong health and prevent diseases like leukemia.

AI Search Multiple angles on this topic

Clinical Impact Beyond Diagnosed Cancer

A single-center retrospective cohort study published in 2025 evaluated clonal hematopoiesis and the clinical impact of myeloid somatic mutations on hematologic and marrow parameters in patients without diagnosed malignancy. Related real-world research in cancer patients examines clonal hematopoiesis, including CHIP and CCUS, in the context of increased comorbidities and risk of myeloid transformation. The available studies therefore address how mutation-defined blood clones may affect patients before or alongside diagnosed malignancy.

What the reported blood-clone figures measure

  • 1.46The corresponding estimate for cancer mortality was 1.46, with a 95% confidence interval of 1.13–1.88.[1]
  • 9.56% of the cohortA separate cohort found driver-gene mutations in 192 people aged 20–69, an overall prevalence of 9.56%.[2]

How to read the risk estimates

These estimates describe associations, not proof that clonal blood changes caused the deaths or cancers. The cardiovascular estimate’s confidence interval includes values on either side of no association, consistent with the source’s stated result.[1]

The different prevalence figures come from different cohorts and measurements, so they are not interchangeable estimates of how common the same mutation-defined condition is in all adults.[2] [3]

The strong cancer-risk association identifies a relationship in the studied data; by itself, it does not establish an individual outcome or explain how the risk arises.[4]

How cohort design shapes the comparisons

The mortality review combined studies with substantial variation in their results and populations, including population cohorts and groups selected for age or disease. That diversity limits how directly its pooled estimates can be applied to any one group.[1]

The paired-sample analysis followed a small group of healthy participants drawn from a large cohort of registered nurses. Its repeated sampling can show whether mutations persist over time in those participants, but does not make the group representative of everyone.[3]

Clonal mutations were reported as stable across time and present in multiple blood-cell compartments, supporting a long-lived stem or progenitor cell as their likely origin. This links the mutations to blood-cell ancestry rather than showing that they themselves cause disease.[3]

In mice lacking Tet2, macrophages showed increased expression of genes involved in atherosclerosis. This is a mechanistic clue from an animal model, not direct evidence of the same effect in people.[5]

What remains unresolved about blood clones

  • How much do the mortality associations vary across population groups and clinical settings, given the differences among the cohorts in the review?[1]
  • Does the link between persistent mutations across blood compartments and a long-lived cell of origin explain later disease risk, or does it mainly reveal cell ancestry?[3]
  • Do the macrophage gene-expression changes seen in Tet2-deficient mice also occur in human blood, and do they contribute to cardiovascular disease?[5]

Sources

  1. Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis (pmc.ncbi.nlm.nih.gov)
  2. Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life - PMC Lock (pmc.ncbi.nlm.nih.gov)
  3. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults (pmc.ncbi.nlm.nih.gov)
  4. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. (www.nejm.org)
  5. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. (www.nejm.org)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What are somatic mutations, and why are they important in understanding our health?

Somatic mutations are genetic changes that occur after conception in the cells of the body, as opposed to inherited mutations that are present from birth. They are significant because they provide a record of cellular history, revealing lineage relationships between blood cells, the rate at which mutations accumulate over a lifetime, and even factors that contribute to diseases. Somatic mutations offer insights into the dynamic processes within our blood system and how they impact overall health.

2

What are hematopoietic stem and progenitor cells (HSPCs), and what role do they play in understanding blood disorders?

Hematopoietic stem and progenitor cells (HSPCs) are the foundational cells of the blood system. Their role is to produce all the different types of blood cells necessary for our survival. They are significant because analyzing the genetic mutations within HSPCs allows researchers to understand how the blood system evolves over time, how mutations accumulate, and what predispositions to blood-related disorders may arise. HSPCs can reveal the underlying processes that lead to conditions like leukemia.

3

What did the research discover about the rate at which mutations accumulate in blood cells, and why is this significant?

The research indicated that mutations accumulate at a relatively steady rate of approximately 14 base substitutions per year. This consistent accumulation is significant because it suggests that the body has an inherent rate of mutagenesis. Most mutations are acquired after birth, highlighting the influence of ongoing internal processes. This discovery offers the potential for interventions that could mitigate these mutagenic processes and potentially reduce the risk of disease.

4

How are mutations in normal blood cells related to diseases like acute myeloid leukemia (AML)?

The research drew parallels between mutation patterns in normal hematopoietic stem and progenitor cells (HSPCs) and those found in acute myeloid leukemia (AML). This is significant because it suggests that the development of leukemia may not necessarily be due to dramatically increased mutagenesis, but rather the selection and expansion of cells that have acquired specific mutations. This changes the understanding of leukemia, suggesting the disease arises from the same underlying processes combined with specific driver mutations.

5

What is the significance of this research in the broader context of understanding blood and overall health?

This study provides a framework for understanding blood cells. By analyzing mutations in the blood cells, a better understanding of lineage relationships, age-related changes, and the origins of blood disorders like leukemia. This understanding could lead to targeted interventions to promote lifelong health and prevent diseases.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.